Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis

Authors:
  • NTNobuyuki Taenaka
    Nobuyuki Taenaka
  • YSYasuhiro Shimada
    Yasuhiro Shimada
  • THTakahiko Hirata
    Takahiko Hirata
  • MNMasako K. Nishijima
    Masako K. Nishijima
  • JTJun Takezawa
    Jun Takezawa
  • IYIkuto Yoshiya
    Ikuto Yoshiya
  • JKJunichi Kambayashi
    Junichi Kambayashi

Abstract
Gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, has an anticoagulant activity in the absence of antithrombin-III. We investigated FOY therapy for the treatment of disseminated intravascular coagulation (DIC) associated with sepsis in 15 patients (group F), and compared it with heparin therapy in 8 patients (group H). Successful treatment was observed in 13 patients in group F and in 4 patients in group H. The efficacy of the therapy in both groups was not significantly different. However, in patients whose antithrombin-III values were less than 20 mg/dl at the initiation of the therapy, FOY therapy was successful in 6 of 7 patients, whereas heparin therapy was not at all successful in 4 patients (p < 0.05). We conclude that FOY can be used as effectively as heparin for the treatment of DIC, and that FOY therapy is superior to heparin therapy in DIC associated with decreased antithrombin-III.